These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32111026)

  • 1. Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology.
    Zolotovskaia MA; Sorokin MI; Petrov IV; Poddubskaya EV; Moiseev AA; Sekacheva MI; Borisov NM; Tkachev VS; Garazha AV; Kaprin AD; Shegay PV; Giese A; Kim E; Roumiantsev SA; Buzdin AA
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.
    Xu C; Nikolova O; Basom RS; Mitchell RM; Shaw R; Moser RD; Park H; Gurley KE; Kao MC; Green CL; Schaub FX; Diaz RL; Swan HA; Jang IS; Guinney J; Gadi VK; Margolin AA; Grandori C; Kemp CJ; Méndez E
    Clin Cancer Res; 2018 Jun; 24(12):2828-2843. PubMed ID: 29599409
    [No Abstract]   [Full Text] [Related]  

  • 3. Pediatric oncology enters an era of precision medicine.
    Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
    Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-biomarker co-development in oncology - 20 years and counting.
    Twomey JD; Brahme NN; Zhang B
    Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 6. An update on genomic-guided therapies for pediatric solid tumors.
    Tsui PC; Lee YF; Liu ZWY; Ip LRH; Piao W; Chiang AKS; Lui VWY
    Future Oncol; 2017 Jun; 13(15):1345-1358. PubMed ID: 28589766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
    Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
    Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
    Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
    Molloy MP; Engel A
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.
    Lee JK; Liu Z; Sa JK; Shin S; Wang J; Bordyuh M; Cho HJ; Elliott O; Chu T; Choi SW; Rosenbloom DIS; Lee IH; Shin YJ; Kang HJ; Kim D; Kim SY; Sim MH; Kim J; Lee T; Seo YJ; Shin H; Lee M; Kim SH; Kwon YJ; Oh JW; Song M; Kim M; Kong DS; Choi JW; Seol HJ; Lee JI; Kim ST; Park JO; Kim KM; Song SY; Lee JW; Kim HC; Lee JE; Choi MG; Seo SW; Shim YM; Zo JI; Jeong BC; Yoon Y; Ryu GH; Kim NKD; Bae JS; Park WY; Lee J; Verhaak RGW; Iavarone A; Lee J; Rabadan R; Nam DH
    Nat Genet; 2018 Oct; 50(10):1399-1411. PubMed ID: 30262818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative omics analyses broaden treatment targets in human cancer.
    Sengupta S; Sun SQ; Huang KL; Oh C; Bailey MH; Varghese R; Wyczalkowski MA; Ning J; Tripathi P; McMichael JF; Johnson KJ; Kandoth C; Welch J; Ma C; Wendl MC; Payne SH; Fenyö D; Townsend RR; Dipersio JF; Chen F; Ding L
    Genome Med; 2018 Jul; 10(1):60. PubMed ID: 30053901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
    Schmidt KT; Chau CH; Price DK; Figg WD
    J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.
    Ortiz MV; Kobos R; Walsh M; Slotkin EK; Roberts S; Berger MF; Hameed M; Solit D; Ladanyi M; Shukla N; Kentsis A
    Pediatr Blood Cancer; 2016 Aug; 63(8):1368-74. PubMed ID: 27082517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-Based Precision Oncology with the Cancer Targetome.
    Blucher AS; Choonoo G; Kulesz-Martin M; Wu G; McWeeney SK
    Trends Pharmacol Sci; 2017 Dec; 38(12):1085-1099. PubMed ID: 28964549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision Oncology: The Road Ahead.
    Senft D; Leiserson MDM; Ruppin E; Ronai ZA
    Trends Mol Med; 2017 Oct; 23(10):874-898. PubMed ID: 28887051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision oncology: current and future platforms for treatment selection.
    Tang X; Berger MF; Solit DB
    Trends Cancer; 2024 Sep; 10(9):781-791. PubMed ID: 39030146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
    Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
    Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Precision oncology and molecular tumor boards].
    Mack E; Horak P; Fröhling S; Neubauer A
    Inn Med (Heidelb); 2024 May; 65(5):462-471. PubMed ID: 38652307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
    Lih CJ; Takebe N
    Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.